Efficacy & Safety of Propranolol Versus Atenolol on the Proliferative

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the efficacy of orally administered propranolol versus atenolol in the treatment of potentially disfiguring or functionally threatening IHs.

Clinical Trial Description

Currently, propranolol is the preferred treatment for problematic proliferating infantile hemangiomas (IHs). Although propranolol is clearly efficacious, rare side effects, such as hypoglycemia, may be life-threatening. The possibility of propranolol resistance and treatment failure is also important, and highlights the need for employing more established techniques in certain cases. Nonselective β-adrenergic antagonists, such as propranolol and timolol, are competitive antagonists of catecholamines at the β1- and β2-adrenergic receptors (β-ARs). β2-AR blockade may result in hypoglycemia as a result of decreased glycogenolysis, gluconeogenesis, and lipolysis. Moreover, bronchial hyperreactivity is a direct effect of nonselective β-blockers, resulting in bronchospasms due to pulmonic β2-AR blockade. A solution to minimize many of the side effects of nonselective β-blocker therapy may be the use of more selective β1-blockers such as metoprolol or atenolol, which, at low dosages, have little β2 activity. Unfortunately, there is a paucity of clinical data comparing the efficacy of selective and non-selective β-blocker. Furthermore, because of the broad heterogeneity of IH (e.g., proliferating versus involuting), confounding with other pharmacologic exposures (e.g., corticosteroids), associated complications (e.g., ulceration) and comorbid medical anomalies (e.g., PHACE) that can influence efficiency after IH treatment, observational studies are unable to definitively establish the clinical utility of β-blockers in IH. Thus, questions regarding the efficacy of the subtypes of β-blockers must be answered in randomized controlled trials, which may provide the only way to overcome the selection and ascertainment bias. The purpose of this study is to compare the efficacy of orally administered propranolol versus atenolol in the treatment of potentially disfiguring or functionally threatening IHs. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02342275
Study type	Interventional
Source	West China Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	October 2013
Completion date	September 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01685398` - Topical Timolol for Superficial Infantile Hemangioma	Phase 3
Withdrawn	`NCT00974129` - A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas	N/A
Completed	`NCT00374335` - Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas	N/A
Recruiting	`NCT03331744` - Clinical Characteristics of Infantile Hemangioma
Completed	`NCT00433940` - Immune Suppression Of Infants Treated With Steroids	N/A
Completed	`NCT04065217` - The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial	N/A
Terminated	`NCT01743885` - Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma	Phase 3
Terminated	`NCT00555464` - Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas	Phase 2
Completed	`NCT00394888` - Hemangioma Associated With High Rates of Morbidity	N/A
Completed	`NCT05327309` - Role of Propranolol as Compared to Bleomycin in Management of Hemangioma	N/A
Completed	`NCT02145884` - Topical Timolol Gel for the Treatment of Infantile Hemangiomas	Phase 2
Completed	`NCT04077515` - Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma	Phase 4
Completed	`NCT02731287` - Topical Timolol for Infantile Hemangioma in Early Proliferative Phase	Phase 2
Recruiting	`NCT01147601` - Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas	Phase 0
Completed	`NCT01908972` - The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma	Phase 4
Completed	`NCT00540566` - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed	`NCT00001417` - Direct Injection of Alcohol for the Treatment of Spinal Tumors	N/A
Completed	`NCT00004436` - Randomized Study of Hormonal Regulation of Infantile Hemangioma	N/A
Recruiting	`NCT02496013` - Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB	Phase 1
Completed	`NCT01072045` - Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms